Recombinant therapeutic proteins: Production platforms and challenges

Biotechnology Journal

Volumn 3, Issue 1, 2008, Pages 90-97

  Dingermann, Theo ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Biotechnologicals; Glycosylation; Post expression modification; Recombinant proteins; Safety

Indexed keywords

POST EXPRESSION MODIFICATION; RECOMBINANT THERAPEUTIC PROTEIN;

ANTIBODIES; BIOTECHNOLOGY; ENZYMES; GLYCOSYLATION; PHARMACOKINETICS; PROTEINS;

DRUG PRODUCTS;

ALTEPLASE; IMIGLUCERASE; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; NEUTRALIZING ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT PROTEIN; RETEPLASE; TENECTEPLASE;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; DNA MODIFICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ERYTHROCYTE APLASIA; GAUCHER DISEASE; GENE EXPRESSION; GLYCOSYLATION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN VARIANT; RECOMBINANT DNA TECHNOLOGY;

DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 38849126803     PISSN: 18606768     EISSN: None     Source Type: Journal    
DOI: 10.1002/biot.200700214     Document Type: Article

References (25)

1. Cohen, S. N., Chang, A. C., Boyer, H. W., Helling, R.B., Construction of biologically functional bacterial plasmids in vitro. Proc. Natl. Acad. Sci. USA 1973, 70, 3240-3244.
2. Anonymous, Human insulin receives FDA approval. FDA Drug Bull. 1982, 12, 18-19.
3. Sasaki, H., Bothner, B., Dell, A., Fukuda, M., Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J. Biol. Chem. 1987, 262, 12059-12076.
4. Gemmill, T. R., Trimble, R. B., Overview of N- and O-linked oligosaccharide structures found in various yeast species. Biochim. Biophys. Acta 1999, 1426, 227-237.
5. Durelli, L., Verdun, E., Barbero, P., Bergui, M. et al., Every other day interferon-beta 1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicentre study (INCOMIN). Lancet 2002,359, 1453-1460.
6. Gelissen, G. Strasser, A. W. M., Suckow, M., Key and criteria to the selection of an expression platform. In: Gellissen. G. (Ed.), Production of Recombinant Proteins. Wiley-VCH. Weinheim 2005, p. 3.
7. Schmidt, F. R., Recombinant expression systems in the pharmaceutical industry. Appl. Microbiol. Biotechnol. 2004. 65, 363-372.
8. Yin, J., Li, G., Ren, X., Herrler, G., Select what you need: A comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. J. Biotechnol. 2007, 127, 335-347.
9. Anonymous, Dynepo - European Public Assessment Report (Scientific Discussion) 2007: http://www.emea.europa.eu/humandocs/PDFs/EPAR/dynepo/ 012102en6.pdf
10. Wildt, S., Gerngross, T. U., The humanization of N-glycosylation pathways in yeast. Nat. Rev. Microbiol. 2005, 3, 119-128.
11. Bobrowicz, P., Davidson, R. C., Li, H., Potquieter. T.I. et al., Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: Production of complex humanized glycoproteins with terminal galactose. Glycobiology 2004, 14, 757-766.
12. Bell, D. S., Insulin therapy in diabetes mellitus: How can the currently available injectable insulins be most prudently and efficaciously utilised? Drugs 2007, 67, 1813-1827.
13. Dunn, C. J., Goa, K. L., Tenecteplase: A review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. Am. J. Cardiovasc. Drugs 2001, 1, 51-66.
14. Llevadot, J., Giugliano, R. P., Antman, E. M., Bolus fibrinolytic therapy in acute myocardial infarction. JAMA 2001, 286, 442-449.
15. Siebert, U., Sroczynski, G., Rossol, S., Wasem, J. et al., German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003, 52, 425-432.
16. Sinclair, A. M., Elliott, S., Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. J. Pharm. Sci. 2005, 94, 1626-1635.
17. Carter, B., Keen, M., Safety of erythropoiesis stimulating agents in patients on dialysis: Current issues for nephrology nurses. Nephrol. Nurs. J. 2007, 34, 311-315.
18. Pastores, G. M., Weinreb, N. J., Aerts, H., Andria, G. et al., Therapeutic goals in the treatment of Gaucher disease. Semin. Hematol. 2004, 41, 4-14.
19. Van Patten, S. M., Hughes, H., Huff, M. R., Piepenliagen, P.A. et al., Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology 2007, 17, 467-478.
20. Kuhlmann, M., Covic, A., The protein science of biosimilars. Nephrol. Dial. Transplant. 2006, 21, 4-8
21. Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka. E. et al., The absense of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003, 278, 3466-3473.
22. Kessler, M., Goldsmith, D., Schellekens, H., Immunogenicity of biopharmaceuticals. Nephrol. Dial. Transplant. 2006, 21, 9-12.
23. Schellekens, H., Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 2005, 20, 3-9.
24. Schellekens, H., Jiskoot, W. Eprex-associated pure red cell aplasia and leachates. Nat. Biotechnol. 2006, 24, 613-624.
25. Ohashi, T., Sakuma, M., Kitagawa, T., Suzuld, K. et al, Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. Mol. Genet. Metab. 2007, 92, 271-273.